Dynavax Technologies Corporation [NASDAQ: DVAX] loss -4.04% or -0.4 points to close at $9.50 with a heavy trading volume of 2378288 shares. The company report on July 6, 2021 that Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax’s CpG 1018 Adjuvant for Biological E’s COVID-19 Vaccine Candidate.
Biological E to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E’s COVID-19 vaccine candidate, CORBEVAX™.
Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, announced the execution of a commercial supply agreement of Dynavax’s CpG 1018TM advanced adjuvant, for use in BE’s subunit COVID-19 vaccine candidate, CORBEVAX™. The commercial supply agreement extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, BE expects to commence product launch of CORBEVAX™ later this year.
It opened the trading session at $10.1382, the shares rose to $10.25 and dropped to $9.47, the range by which the price of stock traded the whole day. The daily chart for DVAX points out that the company has recorded 105.63% gains over the past six months. However, it is still -165.36% lower than its most recent low trading price.
If we look at the average trading volume of 2.54M shares, DVAX reached to a volume of 2378288 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Dynavax Technologies Corporation [DVAX]:
H.C. Wainwright have made an estimate for Dynavax Technologies Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 07, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $14. The new note on the price target was released on August 03, 2020, representing the official price target for Dynavax Technologies Corporation stock. Previously, the target price had yet another raise to $14, while Evercore ISI analysts kept a Outperform rating on DVAX stock.
The Average True Range (ATR) for Dynavax Technologies Corporation is set at 0.44, with the Price to Sales ratio for DVAX stock in the period of the last 12 months amounting to 9.45. The Price to Book ratio for the last quarter was 10.67, with the Price to Cash per share for the same quarter was set at 1.97.
Trading performance analysis for DVAX stock
Dynavax Technologies Corporation [DVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.26. With this latest performance, DVAX shares gained by 9.70% in over the last four-week period, additionally plugging by 105.63% over the last 6 months – not to mention a rise of 12.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DVAX stock in for the last two-week period is set at 54.48, with the RSI for the last a single of trading hit 52.71, and the three-weeks RSI is set at 54.02 for Dynavax Technologies Corporation [DVAX]. The present Moving Average for the last 50 days of trading for this stock 8.85, while it was recorded at 9.87 for the last single week of trading, and 7.18 for the last 200 days.
Dynavax Technologies Corporation [DVAX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Dynavax Technologies Corporation [DVAX] shares currently have an operating margin of -161.59 and a Gross Margin at +62.78. Dynavax Technologies Corporation’s Net Margin is presently recorded at -161.63.
Return on Total Capital for DVAX is now -29.83, given the latest momentum, and Return on Invested Capital for the company is -30.22. Return on Equity for this stock declined to -224.65, with Return on Assets sitting at -23.80. When it comes to the capital structure of this company, Dynavax Technologies Corporation [DVAX] has a Total Debt to Total Equity ratio set at 371.16. Additionally, DVAX Total Debt to Total Capital is recorded at 78.78, with Total Debt to Total Assets ending up at 61.67. Long-Term Debt to Equity for the company is recorded at 365.63, with the Long-Term Debt to Total Capital now at 77.60.
Reflecting on the efficiency of the workforce at the company, Dynavax Technologies Corporation [DVAX] managed to generate an average of -$307,102 per employee. Receivables Turnover for the company is 2.95 with a Total Asset Turnover recorded at a value of 0.15.Dynavax Technologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.90.
An analysis of insider ownership at Dynavax Technologies Corporation [DVAX]
There are presently around $797 million, or 74.20% of DVAX stock, in the hands of institutional investors. The top three institutional holders of DVAX stocks are: FEDERATED HERMES, INC. with ownership of 12,604,723, which is approximately 5.507% of the company’s market cap and around 0.30% of the total institutional ownership; BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding 10,895,773 shares of the stock with an approximate value of $103.51 million in DVAX stocks shares; and BLACKROCK INC., currently with $81.27 million in DVAX stock with ownership of nearly 4.482% of the company’s market capitalization.
Positions in Dynavax Technologies Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 83 institutional holders increased their position in Dynavax Technologies Corporation [NASDAQ:DVAX] by around 7,963,982 shares. Additionally, 71 investors decreased positions by around 8,217,877 shares, while 26 investors held positions by with 67,684,966 shares. The mentioned changes placed institutional holdings at 83,866,825 shares, according to the latest SEC report filing. DVAX stock had 36 new institutional investments in for a total of 1,583,830 shares, while 20 institutional investors sold positions of 312,207 shares during the same period.